What is the recommended treatment and blood pressure target for a patient with hypertensive nephrosclerosis?

Hypertensive Nephrosclerosis: Treatment and Blood Pressure Targets

For patients with hypertensive nephrosclerosis, target a systolic blood pressure <120 mmHg using standardized office measurement, and initiate treatment with an ACE inhibitor or ARB as first-line therapy. 1

Blood Pressure Targets

The recommended blood pressure target is systolic <120 mmHg when measured using standardized office technique (5-minute rest, automated device, average of three readings). 1 This intensive target is based on evidence showing reduced cardiovascular and all-cause mortality in patients with CKD. 2

• The 2024 ESC guidelines recommend targeting systolic BP to 120-129 mmHg in adults with moderate-to-severe CKD (eGFR >30 mL/min/1.73 m²) if tolerated. 1
• For patients with CKD, systolic BP should be lowered to a range of 130-139 mmHg as a minimum target. 1
• It is critical that this <120 mmHg target applies ONLY to standardized BP measurements—applying this target to routine office BP measurements risks dangerous overtreatment. 1

Important Caveats on BP Targets

• In older adults (≥65 years), target systolic BP to 130-139 mmHg. 1
• The evidence for intensive BP control (<120 mmHg) is less robust in patients with diabetes, advanced CKD (stage 4-5), or proteinuria >1 g/day—shared decision-making is essential in these subgroups. 2
• Diastolic BP should not be lowered below 80 mmHg. 1

First-Line Antihypertensive Therapy

ACE inhibitors or ARBs are the preferred first-line agents for hypertensive nephrosclerosis, particularly when albuminuria is present. 1

Specific Indications for RAS Blockade

• ACE inhibitors or ARBs are strongly recommended for patients with eGFR <60 mL/min/1.73 m² AND albuminuria ≥300 mg/g creatinine because they reduce progression to ESRD. 1
• RAS blockers are more effective than other antihypertensives at reducing albuminuria and are recommended when microalbuminuria or proteinuria is present. 1
• For lower levels of albuminuria (30-299 mg/g), ACE inhibitor or ARB therapy reduces progression to more advanced albuminuria and cardiovascular events, though not progression to ESRD. 1

Evidence from Clinical Trials

• The AASK trial demonstrated that ramipril (ACE inhibitor) was superior to metoprolol (beta-blocker) or amlodipine (calcium channel blocker) in slowing GFR decline in African Americans with hypertensive nephrosclerosis, with risk reductions of 22% and 38% respectively. 3
• Importantly, the AASK trial found no additional benefit from targeting mean arterial pressure ≤92 mmHg versus 102-107 mmHg, though this predates the SPRINT trial evidence. 3

Combination Therapy Strategy

Most patients with hypertensive nephrosclerosis require multiple antihypertensive agents to achieve BP targets. 4

When to Use Combination Therapy

• When BP is ≥140/90 mmHg, initiate combination therapy with a RAS blocker (ACE inhibitor or ARB) plus either a dihydropyridine calcium channel blocker or thiazide-type diuretic. 1
• Single-pill fixed-dose combinations are strongly preferred to improve adherence. 1
• In 15-20% of hypertensive patients, three drugs are needed: the most rational combination is a RAS blocker, calcium channel blocker, and diuretic at effective doses. 1

Additional Agents

• Thiazide or thiazide-like diuretics (chlorthalidone, hydrochlorothiazide) are appropriate as add-on therapy. 1
• For resistant hypertension, add low-dose spironolactone to existing treatment after reinforcing sodium restriction. 1
• Avoid combining ACE inhibitors with ARBs—this combination increases adverse events (hyperkalemia, acute kidney injury) without additional benefit. 1

Monitoring and Safety

Laboratory Monitoring

• Monitor serum creatinine and potassium within 2-4 weeks after initiating or uptitrating RAS blockers. 1
• Do not discontinue ACE inhibitor or ARB if serum creatinine increases up to 30% from baseline, provided the increase is stable. 1
• Stop RAS blockade if kidney function continues to worsen beyond 30% or if refractory hyperkalemia develops. 1

Managing Hyperkalemia

• Use potassium-wasting diuretics and/or potassium-binding agents to normalize serum potassium, allowing continuation of RAS blockade for BP control and proteinuria reduction. 1
• Treat metabolic acidosis (serum bicarbonate <22 mmol/L) as this contributes to hyperkalemia. 1

Lifestyle Modifications

Lifestyle interventions are synergistic with pharmacologic therapy and should be implemented in all patients. 1

• Restrict dietary sodium to <2 g/day (<90 mmol/day, or <5 g sodium chloride/day). 1
• Undertake moderate-intensity physical activity for at least 150 minutes per week or to a level compatible with cardiovascular tolerance. 1
• Normalize weight and stop smoking. 1
• Counsel patients to hold ACE inhibitor/ARB and diuretics during acute illness or volume depletion ("sick day rules"). 1

Diagnostic Considerations

The diagnosis of hypertensive nephrosclerosis is often presumptive and based on clinical criteria with low diagnostic accuracy. 5, 6

• Current clinical criteria have very low sensitivity (0.13) but high specificity (0.94) for biopsy-verified arterionephrosclerosis. 5
• Consider kidney biopsy in selected patients to exclude treatable alternative diagnoses (glomerulonephritis, interstitial nephritis, APOL1-associated glomerulosclerosis), as 40% of clinically diagnosed cases may have other pathology. 5, 7
• In patients of recent African ancestry, consider APOL1 genetic testing, as APOL1-associated glomerulosclerosis is distinct from hypertension-induced nephropathy and belongs to the focal segmental glomerulosclerosis spectrum. 7

Follow-Up Strategy

• Schedule monthly follow-up visits for dose titration until target BP is achieved. 8
• Use standardized office BP measurement at every visit—automated office BP (attended or unattended) is the preferred method. 1
• Consider out-of-office BP monitoring (ambulatory or home BP monitoring) to complement office readings and detect white coat or masked hypertension. 1